Influenza A virus subtype H5N3

From WikiMD's WELLNESSPEDIA

Influenza A virus subtype H5N3 is a subtype of the Influenza A virus that primarily affects birds, but can occasionally infect humans and other animals. It is a subtype of the species Influenza A virus of the genus Influenzavirus A in the family Orthomyxoviridae.

History[edit]

The H5N3 subtype was first identified in Scotland in 1963, during an outbreak of avian influenza in turkeys. Since then, it has been detected in various bird species worldwide, including ducks, geese, and chickens.

Structure and Classification[edit]

Like all Influenza A viruses, H5N3 is an Orthomyxovirus and has a segmented genome composed of eight single-stranded negative-sense RNA segments. The H5N3 subtype is classified based on the antigenic properties of its two surface glycoproteins, Hemagglutinin (H) and Neuraminidase (N).

Pathogenesis and Transmission[edit]

H5N3 is highly pathogenic in birds, causing severe disease and high mortality rates. Transmission occurs primarily through direct contact with infected birds or their secretions, but can also occur through contact with contaminated environments.

Prevention and Control[edit]

Prevention and control of H5N3 outbreaks in poultry involve biosecurity measures, surveillance, and vaccination. In humans, antiviral drugs such as Oseltamivir can be used for treatment and prophylaxis.

See Also[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.